Aripiprazole treatment of risperidone-induced hyperprolactinemia

Journal of Clinical Psychiatry

Volumn 70, Issue 7, 2009, Pages 1058-1059

  Chen, Jing Xu ^a   Su, Yun Ai ^b   Wang, Shao Li ^a   Bian, Qing Tao ^a   Liu, Yan Hong ^a   Wang, Ning ^a   Yang, Fu De ^a   Haile, Colin ^c   Kosten, Thomas R ^c   Zhang, Xiang Yang ^a,c  

^a BEIJING HUILONGGUAN HOSPITAL   (China)

^b PEKING UNIVERSITY SIXTH HOSPITAL   (China)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; PROLACTIN; RISPERIDONE;

ANOREXIA; BLOOD SAMPLING; CHINESE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG INDUCED HEADACHE; HUMAN; HYPERPROLACTINEMIA; LETTER; MALE; MORNING DOSAGE; OPEN STUDY; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROSPECTIVE STUDY; SCHIZOPHRENIA; TACHYCARDIA; TREATMENT DURATION;

ANTIPSYCHOTIC AGENTS; HUMANS; HYPERPROLACTINEMIA; PIPERAZINES; PROSPECTIVE STUDIES; QUINOLONES; RISPERIDONE; SCHIZOPHRENIA;

EID: 68049148516     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.08l04671     Document Type: Letter

References (15)

1. Jung DU, Seo YS, Park JH, et al. The prevalence of hyperprolactinemia after long-term haloperidol use in patients with chronic schizophrenia. J Clin Psychopharmacol. 2005;25(6):613-615.
2. Kessler RM. Aripiprazole: what is the role of dopamine D2 receptor partial agonism? Am J Psychiatry. 2007;164(9):1310-1312.
3. 1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland. J Pharmacol Exp Ther. 1996;277(1):137-143.
4. Mir A, Shivakumar K, Williamson RJ, et al. Change in sexual dysfunction with aripiprazole: a switching or add-on study. J Psychopharmacol. 2008;22(3):244-253.
5. Lee BH, Kim YK, Park SH. Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(4):714-717.
6. Shim JC, Shin JG, Kelly DL, et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry. 2007;164(9):1404-1410.
7. Chen CH, Lu ML. Aripiprazole resolves symptomatic hyperprolactinemia in a male schizophrenic patient. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(3):893-894.
8. Wahl R, Ostroff R. Reversal of symptomatic hyperprolactinemia by aripiprazole. Am J Psychiatry. 2005;162(8):1542-1543.
9. Kay SR, Opler LA, Fizbein A. The Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health System; 1986.
10. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health; 1976:218-222.
11. Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676.
12. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11-19.
13. El-Sayeh HG, Morganti C, Adams CE. Aripiprazole for schizophrenia: systematic review. Br J Psychiatry. 2006;189:102-108.
14. Grunder G, Carlsson A, Wong DF. Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch Gen Psychiatry. 2003;60(10):974-977.
15. Aihara K, Shimada J, Miwa T, et al. The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release. Brain Res. 2004;1003(1-2):9-17.